Featured Research

from universities, journals, and other organizations

Can the addition of radiolabeled treatments improve outcomes in advanced metastatic disease?

Date:
November 13, 2012
Source:
Mary Ann Liebert, Inc., Publishers
Summary:
Radiolabeled agents are powerful tools for targeting and killing cancer cells and may help improve outcomes and lengthen survival times of patients with advanced disease that has spread beyond the initial tumor site. Effective therapy for metastatic cancer requires acombination of treatments, and the benefits of adding radionuclide therapy are explored in three studies.

Radiolabeled agents are powerful tools for targeting and killing cancer cells and may help improve outcomes and lengthen survival times of patients with advanced disease that has spread beyond the initial tumor site. Effective therapy for metastatic cancer requires acombination of treatments, and the benefits of adding radionuclide therapy are explored in three studies published in Cancer Biotherapy and Radiopharmaceuticals, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

Related Articles


The articles are available free on the Cancer Biotherapy and Radiopharmaceuticals website (http://www.liebertpub.com/cbr).

"The preliminary therapeutic results reported in these case studies using radionuclide multimodality approaches are encouraging," says Co-Editor-in-Chief Donald J. Buchsbaum, PhD, Division of Radiation Biology, Department of Radiation Oncology, University of Alabama at Birmingham. "The outcomes described in these small, single center studies must be confirmed in larger trials before they can be translated into widespread oncology practice."

J. Harvey Turner, MD, FRACP, The University of Western Australia, Fremantle, coauthored two of the case studies and, in the Perspective article "Multimodality Radionuclide Therapy of Progressive Disseminated Lymphoma and Neuroendocrine Tumors as a Paradigm for Cancer Control," he states that the synergistic effects that can be achieved by combining chemotherapy and radionuclides "has the potential to enhance efficacy and minimize toxicity." Although advanced forms of lymphoma and neuroendocrine tumors are usually incurable, multimodal treatment approaches may be able to stop or slow tumor progression, achieve durable remission, prolong patient survival, and improve their quality of life.

Paul Kruger, Julian Cooney, and J. Harvey Turner report that more patients survived longer and were free of disease when a radioimmunotherapeutic agent was added to their treatment regimen in the article "Iodine-131 Rituximab Radioimmunotherapy with BEAM Conditioning and Autologous Stem Cell Transplant Salvage Therapy for Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma."

Phillip Claringbold, Richard Price, and J. Harvey Turner added a lutetium-177 labeled peptide to the therapeutic regimen of a group of patients with advanced neuroendocrine cancer and described substantially improved tumor control rates with no significant side effects. They report their findings in "Phase I-II Study of Radiopeptide 177Lu-Octreotate in Combination with Capecitabine and Temozolomide in Advanced Low-Grade Neuroendocrine Tumors."


Story Source:

The above story is based on materials provided by Mary Ann Liebert, Inc., Publishers. Note: Materials may be edited for content and length.


Journal References:

  1. J. Harvey Turner. Perspective: Multimodality Radionuclide Therapy of Progressive Disseminated Lymphoma and Neuroendocrine Tumors as a Paradigm for Cancer Control. Cancer Biotherapy & Radiopharmaceuticals, 2012; 27 (9): 525 DOI: 10.1089/cbr.2012.1274
  2. Paul C. Kruger, Julian P. Cooney, J. Harvey Turner. Iodine-131 Rituximab Radioimmunotherapy with BEAM Conditioning and Autologous Stem Cell Transplant Salvage Therapy for Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma. Cancer Biotherapy & Radiopharmaceuticals, 2012; 27 (9): 552 DOI: 10.1089/cbr.2012.1275
  3. Phillip G. Claringbold, Richard A. Price, J. Harvey Turner. Phase I-II Study of Radiopeptide177Lu-Octreotate in Combination with Capecitabine and Temozolomide in Advanced Low-Grade Neuroendocrine Tumors. Cancer Biotherapy & Radiopharmaceuticals, 2012; 27 (9): 561 DOI: 10.1089/cbr.2012.1276

Cite This Page:

Mary Ann Liebert, Inc., Publishers. "Can the addition of radiolabeled treatments improve outcomes in advanced metastatic disease?." ScienceDaily. ScienceDaily, 13 November 2012. <www.sciencedaily.com/releases/2012/11/121113121839.htm>.
Mary Ann Liebert, Inc., Publishers. (2012, November 13). Can the addition of radiolabeled treatments improve outcomes in advanced metastatic disease?. ScienceDaily. Retrieved October 25, 2014 from www.sciencedaily.com/releases/2012/11/121113121839.htm
Mary Ann Liebert, Inc., Publishers. "Can the addition of radiolabeled treatments improve outcomes in advanced metastatic disease?." ScienceDaily. www.sciencedaily.com/releases/2012/11/121113121839.htm (accessed October 25, 2014).

Share This



More Health & Medicine News

Saturday, October 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com
Doctor in NYC Quarantined With Ebola

Doctor in NYC Quarantined With Ebola

AP (Oct. 24, 2014) An emergency room doctor who recently returned to the city after treating Ebola patients in West Africa has tested positive for the virus. He's quarantined in a hospital. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins